Leukemia combo study pulled before enrolling a single patient
NCT ID NCT07428486
First seen Feb 27, 2026 · Last updated May 15, 2026 · Updated 11 times
Summary
This study was designed to find safe doses of two experimental drugs (lisaftoclax and pelcitoclax) when given with standard FLAG chemotherapy for adults with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL). The goal was to control the disease by killing cancer cells. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOBLASTIC LEUKEMIA ACUTE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.